Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>Investigate the gut microbiome in progressive multiple sclerosis (MS) and how it relates to clinical disease.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We sequenced the microbiota from healthy controls, relapsing remitting MS (RRMS), and progressive MS patients and correlated the levels of bacteria with clinical features of disease, including EDSS, quality of life, and brain MRI lesions/atrophy. We colonized mice with MS‐derived <i>Akkermansia</i> and induced experimental autoimmune encephalomyelitis. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Microbiota β‐diversity differed between MS patients vs. controls but did not differ between RRMS vs. progressive MS or differ based on disease modifying therapies. Disease status had the greatest effect on the microbiome β‐diversity, followed by BMI, race, and sex. In both progressive and RRMS, we found increased <i>Clostridium bolteae, Ruthenibacterium lactatiformans</i> and <i>Akkermansia</i> and decreased <i>Blautia wexlerae</i>, <i>Dorea formicigenerans</i>, and <i>Erysipelotrichaceae CCM</i>. Unique to progressive MS, we found elevated <i>Enterobacteriaceae</i> and <i>Clostridium g24 FCEY</i> and decreased <i>Blautia</i> and <i>Agathobaculum</i>. Several <i>Clostridium</i> species were associated with higher EDSS and fatigue scores. Contrary to the view that elevated <i>Akkermansia</i> in MS has a detrimental role, we found that <i>Akkermansia</i> was linked to lower disability, suggesting a beneficial role. Consistent with this, we found that <i>Akkermansia</i> isolated from MS patients ameliorated EAE, which was linked to a reduction in RORγt+ and IL‐17 producing γδ T cells. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Interpretation</h3><p>While some microbiota alterations are shared in relapsing and progressive MS, we identified unique bacteria associated with progressive MS and clinical measures of disease. Furthermore, elevated <i>Akkermansia</i> in MS may be a compensatory beneficial response in the MS microbiome. </p><p>This article is protected by copyright. All rights reserved.</p></section>

Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study

Identification of commensal gut microbiota signatures as predictors of clinical severity and disease progression in multiple sclerosis

Changes in Gut Microbiota in Patients with Multiple Sclerosis Based on 16s rRNA Gene Sequencing Technology: A Review and Meta-Analysis

Meta-analysis identifies common gut microbiota associated with multiple sclerosis

Expression of Inflammatory Mediators in Biofilm Samples and Clinical Association in Multiple Sclerosis Patients in Remission—A Pilot Study

Alterations of the Fecal Microbiota in Chinese Patients with Multiple Sclerosis

Multiple sclerosis patients have an altered gut mycobiome and increased fungal to bacterial richness

The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes

The Gut Microbiota and Associated Metabolites in Multiple Sclerosis

Variations in diet cause alterations in microbiota and metabolites that follow changes in disease severity in a multiple sclerosis model

Gut Microbiome in Progressive Multiple Sclerosis

Modulation of multiple sclerosis risk and pathogenesis by the gut microbiota: Complex interactions between host genetics, bacterial metabolism, and diet

Utility of an Untargeted Metabolomics Approach Using a 2D GC-GC-MS Platform to Distinguish Relapsing and Progressive Multiple Sclerosis

Mining for microbial metabolites associated with disease progression in an age-dependent model of experimental autoimmune encephalomyelitis

High-Throughput Combined Analysis of Saliva Microbiota and Metabolomic Profile in Chinese Periodontitis Patients: A Pilot Study

Metabolomics of Multiple Sclerosis Lesions Demonstrates Lipid Changes Linked to Alterations in Transcriptomics-Based Cellular Profiles

The Multiple Sclerosis Gut Microbiota: A Systematic Review

Metabolomics analysis in saliva from periodontally healthy, gingivitis and periodontitis patients.

Predictive Metagenomic Analysis of Autoimmune Disease Identifies Robust Autoimmunity and Disease Specific Microbial Signatures

Short-chain fatty acid producers in the gut are associated with pediatric multiple sclerosis onset

Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis